| Document |
Document Title |
|
WO/2023/249071A1 |
[Problem] To provide a novel T-cell receptor (TCR) which specifically recognizes glypican 3 (GPC3). [Solution] Provided is a T-cell receptor (TCR) that includes one amino acid sequence selected from the group consisting of the amino acid...
|
|
WO/2023/249934A1 |
Provided are methods of genetically modifying cells. In certain embodiments, the methods comprise modifying a coding region of a mitochondrial gene of the cell. According to some embodiments, the modification results in increased transla...
|
|
WO/2023/246012A1 |
Provided is a method for separating and extracting multiple subpopulations of gastric cancer tissue-derived extracellular vesicles, comprising: firstly immersing a tumor tissue into a digestive juice for enzymolysis digestion to obtain a...
|
|
WO/2023/246911A1 |
The present invention relates to a T cell receptor-based bispecific polypeptide molecule and use thereof. The present invention further provides a nucleic acid encoding the polypeptide molecule of the present invention, a vector or a vec...
|
|
WO/2023/246820A1 |
Provided are a compound for inducing a stem cell-like memory cell in vitro, and an application thereof. The compound is as shown in the following formula (I) or (II), and has glycogen synthase kinase 3 inhibitory activity. After combined...
|
|
WO/2023/249104A1 |
The present invention addresses the problem of providing a system for, when producing a single type of cellular product using at least two types of tissue derived from the same patient, ultimately providing said single type of cellular p...
|
|
WO/2023/246626A1 |
Provided are a cell with targeted integration, a method for preparing same, and a method for producing a target gene expression product. The cell with targeted integration comprises a nucleic acid fragment set forth in SEQ ID NO. 1 compr...
|
|
WO/2023/245283A1 |
There is described herein methods of ameliorating, treating or preventing graft-versus- host disease, transplant rejection or an autoimmune disorder, or promoting transplant graft function in a human using innate lymphoid cells (ILCs), i...
|
|
WO/2023/246325A1 |
Disclosed are a nanobody (Nb) targeting CD73, a nanobody-drug conjugate (NDC), a preparation method therefor and use thereof. The monoclonal nanobody and the corresponding NDC of the present invention can efficiently and specifically bin...
|
|
WO/2023/247324A1 |
The present invention relates to a combination of adoptively transferred cells (adoptive cells) and at least one anti-PDL1/PD1 antibody, wherein the adoptive cells comprises natural killer (NK) lymphocytes and T lymphocytes obtained by a...
|
|
WO/2023/248934A1 |
A method for producing a cell support composite 10 includes: culturing renal cells in an aggregated state; separating the aggregates into individual cultured cells 16; seeding the cultured cells 16 onto a substrate 12 at a seeding densit...
|
|
WO/2023/247733A1 |
The present disclosure provides a process for producing recombinant viral vectors in eukaryotic cells. In particular, the present disclosure relates to a process for the transient transfection of eukaryotic cells for production of recomb...
|
|
WO/2023/246247A1 |
The present invention relates to a pharmaceutical composition, comprising an anti-CD73 (for example, human CD73) antibody or an antigen-binding fragment thereof, and an anti-PD-1-anti-VEGFA bispecific antibody or an antigen-binding fragm...
|
|
WO/2023/249963A1 |
Application of adeno-associated virus (AAV) vectors in large animal studies and clinical trials often requires high-titer and high-potency vectors manufactured at a scale that can support large doses and/or large populations. A number of...
|
|
WO/2023/246003A1 |
Provided are a chimeric antigen receptor macrophage, a method for preparing same, and use thereof. The chimeric antigen receptor macrophage is a mouse bone marrow-derived macrophage comprising a chimeric antigen receptor modification and...
|
|
WO/2023/246642A1 |
Disclosed are a composition for treating spinal cord injury, a preparation method therefor and a use thereof. The composition comprises induced neural stem cells, fibrin and thrombin, and is particularly applicable for fully injured and ...
|
|
WO/2023/246644A1 |
The present invention provides a spinal progenitor cell for treating amyotrophic lateral sclerosis (ALS). The spinal progenitor cell is represented as at least any two of PAX6+, SOX1+, Nkx6.1+, SOX2+, DBX2+, OLIG2+, PAX3+, or Nkx2.2+, an...
|
|
WO/2023/246004A1 |
Disclosed are a chimeric antigen receptor, a macrophage expressing same, and use. A primary protein structure of the chimeric antigen receptor comprises sequentially from the amino terminus to the carboxyl terminus: a signal peptide, an ...
|
|
WO/2023/246908A1 |
Provided are preparation and use of a chimeric antigen receptor immune cell targeting CSF1R. Specifically, provided is a chimeric antigen receptor (CAR) modified on the basis of a natural CSF1R ligand, the CAR comprising an extracellular...
|
|
WO/2023/247532A1 |
Cardiovascular diseases represent the leading cause of mortality and accounts for approximately one-third of deaths globally each year. During the last decade, tremendous efforts have been made to take advantage of advances in regenerati...
|
|
WO/2023/246578A1 |
A chimeric antigen receptor specifically binding to GPC3, a modified immune cell expressing the chimeric antigen receptor, and a method for preparing the modified immune cell. These chimeric antigens and immune cells are used for a metho...
|
|
WO/2023/249065A1 |
A tissue regeneration promotion sheet (10) comprises a cell retention sheet (12), which is a non-woven fabric that contains fibers mainly composed of polycaprolactone and are capable of allowing permeation of a cell suspension containing...
|
|
WO/2023/250485A1 |
The present disclosure provides reporter T cells expressing a γδ T cell receptor (TCR) and a reporter gene, wherein the reporter gene is expressed when the T cell is activated. Also provided are assays that utilize the modified T cells...
|
|
WO/2023/250400A1 |
Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express re...
|
|
WO/2023/247007A1 |
The present invention relates to a method for creating organoids, each organoid simulating a biological organ having an organ development state. A substrate (01) is provided, which has a plurality of cavities (02), each cavity being desi...
|
|
WO/2023/248620A1 |
Provided is a cell culture vessel that: has a thickness of 5 µm or less; enables a further increase in viability through improvement in oxygen permeability even with several hundreds of nm; does not require precise molding; can be easil...
|
|
WO/2023/245801A1 |
Provided in the present application are an anti-candida mannan monoclonal antibody and the use thereof. The monoclonal antibody is a rabbit-derived monoclonal antibody, has multiple antigen recognition sites, good specificity and high af...
|
|
WO/2023/245670A1 |
The invention described herein provides methods and compositions for treating certain diseases, using a composition for regulating a primate PTBP gene expression comprising a Cas effector protein and a guide RNA (gRNA) to target a target...
|
|
WO/2023/250101A1 |
Featured are methods, compositions, and apparatuses for the in vitro maturation of oocytes. In particular, the disclosure features methods of inducing oocyte maturation in vitro, by co-culturing a female subject's oocytes with an ex vivo...
|
|
WO/2023/249463A1 |
The present invention relates to an immune cell expressing an immune checkpoint regulator so as to overcome an immune checkpoint, a preparation method therefor, and a pharmaceutical composition comprising the immune cell, and, more speci...
|
|
WO/2023/248870A1 |
This endoribonuclease comprises the amino acid sequence of (a) or (b) below and hydrolyzes the phosphodiester bond between U and A in 5'-UACU-3' or 5'-UACG-3' included in RNA. (a) An amino acid sequence represented by SEQ ID NO: 1. (b) A...
|
|
WO/2023/246001A1 |
Disclosed is use of the combination of CAR-T and CAR-M in the preparation of an antitumor medicament. CAR-T is a T cell modified by a chimeric antigen receptor; the primary protein structure of the chimeric antigen receptor sequentially ...
|
|
WO/2023/246485A1 |
Disclosed are a construction method for a 3D stratum corneum-like model and use thereof. The 3D stratum corneum-like model is composed of a top surface, an intermediate layer, and a bottom surface. The top and bottom surfaces are uneven ...
|
|
WO/2023/250440A1 |
Extracellular vesicles comprising a bi-layer lipid membrane comprising an inner layer and an outer layer and a first recombinant protein comprising a first transmembrane moiety embedded between the inner layer and the outer layer of the ...
|
|
WO/2023/246266A1 |
Provided is a method for simultaneously preparing a single cell suspension and a single cell nucleus suspension in the same mouse kidney tissue sample, and simultaneously performing single cell sequencing and single cell nucleus sequenci...
|
|
WO/2023/249363A1 |
The present invention relates to a composition that substitutes for fetal bovine serum (FBS). More specifically, the composition includes an insect protein hydrolysate for use in cell cultures and when used for various animal-derived cel...
|
|
WO/2023/245813A1 |
Provided are a composition and the use thereof in preparation of a cell membrane. The composition comprises an ITS cell culture additive, dexamethasone and vitamin C. The composition can be used to prepare a cell membrane by means of a g...
|
|
WO/2023/241391A1 |
The present invention provides a TCR molecule binding to an SSX2 antigen and an application thereof. The TCR molecule can specifically bind to an SSX2 antigen short peptide complex AQIPEIQK-HLA A1101. Meanwhile, effector cells transducin...
|
|
WO/2023/245109A2 |
Compositions and methods for ex vivo genomic editing using Neisseria meningitidis (Nme) CRISPR/Cas9 systems are disclosed. The present disclosure provides for engineered cells comprising a genetical modification for use e.g., in adoptive...
|
|
WO/2023/243960A1 |
The present invention relates to an extracellular vesicle mass production method using a cell spheroid embedded with a microparticle having a differentiation stimulating factor supported therein, and the extracellular vesicle obtained th...
|
|
WO/2023/244053A1 |
The present invention relates to a medium composition for producing nasal mucosal organoids and a method for producing nasal mucosal organoids, the method comprising the step of culturing cells derived from a nasal mucosal tissue in the ...
|
|
WO/2023/240336A1 |
Systems and methods for growing cells or cell sheets are described. The method may use biocompatible or food-safe materials. The method may allow for cell alignment, optionally in selected patterns, which may be produced by casting a mem...
|
|
WO/2023/241493A1 |
Provided are an antibody specifically binding to Trop2 or an antigen-binding fragment thereof, a preparation method therefor and use thereof, which relate to the technical field of biological immunotherapies. The antibody has good safety...
|
|
WO/2023/243934A1 |
The present invention relates to a composition comprising primed functionally-enhanced stem cells for preventing, ameliorating or treating arthritis, a stem cell therapeutic agent, and a method for preparing same. Stem cells primed by tr...
|
|
WO/2023/242231A1 |
Provided herein are methods relating to making non-natively occurring myogenic cells. For example, provided herein are methods for transdifferentiating a liver-derived cell to a non- natively occurring myogenic cell. In another example, ...
|
|
WO/2023/243495A1 |
Provided is a method capable of expressing and activating the function of a G-protein conjugated receptor (GPCR). A method for expressing a GPCR polypeptide comprises expressing, in a cell, a GPCR polypeptide comprising an amino acid seq...
|
|
WO/2023/242209A1 |
The invention is directed to a device for sperm cell selection having a support plate comprising an inlet to receive a sample of sperm cells, an outlet to collect at least some of the sperm cells comprised in said sample, and a microflui...
|
|
WO/2023/240483A1 |
Provided are a method for preparing a T cell expressing a functional molecule, comprising the steps of: 1) resuscitating and alleviating a PBMC for 1-4 hours; 2) sorting and activating a CD3+ T cell for 10-36 hours by means of the PBMC; ...
|
|
WO/2023/240763A1 |
Disclosed in the present invention are a method for inducing the differentiation of iPSCs to obtain CD34+ cells and NK cells and the use thereof. According to the method, using the three-dimensional structure of an embryoid body to provi...
|
|
WO/2023/241094A1 |
Provided in the present invention is a method for preparing a tissue engineering liver on the basis of a plant decellularized scaffold. The method comprises the following steps: S1, cutting out the stem of hollow water celery; S2, immers...
|
